Sponsored By

Vitafoods Europe

Sabinsa spotlights C3 Reduct curcuminoid: the first to deliver curcumin as a metabolite [Interview]Sabinsa spotlights C3 Reduct curcuminoid: the first to deliver curcumin as a metabolite [Interview]

At this year’s Vitafoods Europe, Sabinsa will focus attention on its C3 Reduct curcuminoid metabolite ingredient – the first to have been granted Novel Foods approval by the European Food Safety Authority (EFSA). Sabinsa’s President of European Operations Dr Umar Jan tells Vitafoods Insights just what makes this product so exciting.

Paul Gander, Freelance editor and journalist

April 10, 2023

3 Min Read
Sabinsa spotlights C3 Reduct curcuminoid: the first to deliver curcumin as a metabolite
© Vitafoods

Dr Jan, with so many curcumin products on the market, what is so different about yours?

“It’s true that wider recognition of the health benefits of curcumin and of the turmeric spice it’s sourced from has led to a huge growth in the supply of this ingredient. But with brand-owners and consumers now more aware than ever of the question of bioavailability, our Curcumin C3 Reduct product stands out.”

“Ours is the only concentrated and enhanced ingredient of its type, where the curcuminoids are already converted to Tetrahydrocurcuminoids (THCs). This product contains pharmacologically active metabolites of curcuminoids. It can swing into action inside the cells immediately – and provide measurable health benefits.”

“The fact that THCs are colourless or white, in contrast to brightly-coloured curcumin, also provides an advantage for formulators.”

Why select this particular curcuminoid?

“Well, since we are on the topic of product formulation, there are other ways in which THCs offer greater versatility than alternative curcumin products. For example, THCs have demonstrated higher stability over a wide pH range than curcumin itself, demethoxycurcumin or bisdemethoxycurcumin – all of them significant components of turmeric.”

“Additionally, THCs are pharmacologically active metabolites of curcuminoids, and most of the health benefits of curcuminoids are attributed to the presence of these reductive metabolites – here in the form of C3 Reduct. Specifically, C3 Reduct has been shown in several studies to outperform curcumin on pharmacological activity. Other curcumin metabolites such as curcumin glucuronide and curcumin sulphate are biologically inactive.”

What are the details of the Novel Food status for C3 Reduct?

“The approval confirms that our product fulfils all safety requirements. It is approved for use as a food supplement for adults, with an upper limit on dosage of 140mg per day.”

What does the science tell us about the health benefits?

“It is thanks to the solid science behind C3 Reduct, of course, that we have the Novel Foods approval from EFSA. In terms of outcomes, targeted research has shown that C3 Reduct can support the health of organs such as the liver, the lungs, the gut – and even the brain.”

“To pick out just some examples, addressing gut health, our curcuminoid has been shown to attenuate inflammatory responses and maintain overall colon health, resulting in reduced formation of colon polyps.”

“Its anti-inflammatory benefits were again evident from studies carried out in the area of liver health. These demonstrate that C3 Reduct has a protective effect against oxidative stress and the damage to this organ that can result.”

“In the case of the brain, the antioxidant and anti-inflammatory function of Sabinsa’s tetrahydrocurcuminoids has been verified in relation to reductions in glutathione, helping to reduce, in turn, neurodegeneration.”

“For the lungs, our product has a demonstrably beneficial impact in helping to mitigate fibrosis, according to unpublished trials, reducing the incidence of key inflammatory markers.”

“Other results of interest include those from trials showing that C3 Reduct can reduce blood glucose, findings which suggest a beneficial role for Sabinsa’s product in managing healthy sugar levels.”

“Last but not least, we should mention the benefits of our curcuminoid in sports nutrition. Once again, it is the well-documented anti-inflammatory properties of the ingredient which offer great promise. Curcumin C3 Reduct is shown to activate 250 times the amount of Adenosine Monophosphate Protein Kinase (AMPK). By the way, AMPK is the central regulator of energy homeostasis, balances the supply of nutrients with energy demand, and stimulates ATP production under energy-depleted conditions. By activating AMPK, C3 Reduct helps to reduce excess glucose and fats, burning them for energy.”

“All in all, Sabinsa’s C3 Reduct delivers a wide array of opportunities for formulators and NPD professionals.”

Meet Umar and the Sabinsa team at their booth B80 during the coming Vitafoods show.

Read more about:

Sponsored ContentVitafoods Europe

About the Author

Paul Gander

Freelance editor and journalist

SUBSCRIBE TO OUR FREE NEWSLETTERS
Get your dose of nutrition science, health ingredient innovations, and nutraceutical R&D!